Enhanced Sensitivity to Sunitinib by Inhibition of Akt1 Expression in Human Castration-resistant Prostate Cancer PC3 Cells Both In Vitro and In Vivo

Urology

Volumn 85, Issue 5, 2015, Pages 1215.e1-1215.e7

  Nishikawa, Masatomo ^a   Miyake, Hideaki ^a   Fujisawa, Masato ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AKT1 PRPTEIN; CLUSTERIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN P42; PROTEIN P44; SHORT HAIRPIN RNA; SUNITINIB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CASTRATION RESISTANT PROSTATE CANCER; CELL GROWTH; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; ENZYME INHIBITION; EXPRESSION VECTOR; GENE SILENCING; GENE TARGETING; GENETIC TRANSFECTION; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR GROWTH; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; HUMAN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TUMOR CELL CULTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; INDOLES; MALE; MICE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTO-ONCOGENE PROTEINS C-AKT; PYRROLES; TUMOR CELLS, CULTURED;

EID: 84937901649     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2015.02.016     Document Type: Article

References (30)

1. R.J. Cersosimo New agents for the management of castration-resistant prostate cancer Ann Pharmacother 46 2012 1518 1528
2. M. Cheung, and J.R. Testa Diverse mechanisms of AKT pathway activation in human malignancy Curr Cancer Drug Targets 13 2013 2340 2344
3. R. Bedolla, T.J. Prihoda, J.I. Kreisberg, and et al. Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation Clin Cancer Res 13 2007 3860 3867
4. P.B. Makhov, K. Golovine, A. Kutikov, and et al. Modulation of Akt/mTOR signaling overcomes sunitinib resistance in renal and prostate cancer cells Mol Cancer Ther 11 2012 1510 1517
5. M.J. Zinda, M.A. Johnson, J.D. Paul, and et al. AKT-1, -2, and -3 are expressed in both normal and tumor tissues of the lung, breast, prostate, and colon Clin Cancer Res 7 2001 2475 2479
6. R. Li, H. Dai, T.M. Wheeler, and et al. Prognostic value of Akt-1 in human prostate cancer: a computerized quantitative assessment with quantum dot technology Clin Cancer Res 15 2009 3568 3573
7. H.K. Gan, B. Seruga, and J.J. Knox Sunitinib in solid tumors Expert Opin Investig Drugs 18 2009 821 834
8. D.B. Mendel, A.D. Laird, X. Xin, and et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship Clin Cancer Res 9 2009 327 337
9. K.J. Gotink, and H.M. Verheul Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis 13 2010 1 14
10. M. Dror Michaelson, M.M. Regan, W.K. Oh, and et al. Phase II study of sunitinib in men with advanced prostate cancer Ann Oncol 20 2009 913 920
11. G. Sonpavde, P.O. Periman, D. Bernold, and et al. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy Ann Oncol 21 2010 319 324
12. K.G. Chen, and B.I. Sikic Molecular pathways: regulation and therapeutic implications of multidrug resistance Clin Cancer Res 18 2012 1863 1869
13. I. Sakai, H. Miyake, and M. Fujisawa Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumour cell proliferation BJU Int 112 2012 E211 E220
14. T. Terakawa, H. Miyake, J. Furukawa, and et al. Enhanced sensitivity to androgen withdrawal due to overexpression of interleukin-6 in androgen-dependent human prostate cancer LNCaP cells Br J Cancer 101 2009 1731 1739
15. M. Kumano, H. Miyake, T. Kurahashi, and et al. Enhanced progression of human prostate cancer PC3 cells induced by the microenvironment of the seminal vesicle Br J Cancer 98 2008 356 362
16. H. Yoon, D.J. Kim, E.H. Ahn, and et al. Antitumor activity of a novel antisense oligonucleotide against Akt1 J Cell Biochem 108 2009 832 838
17. M. Yanagihara, M. Katano, N. Takahashi-Sasaki, and et al. Ribozymes targeting serine/threonine kinase Akt1 sensitize cells to anticancer drugs Cancer Sci 96 2005 620 626
18. J. Wang, J. Gao, Q. Lei, and et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer Cancer Cell 4 2003 209 221
19. T. Sasaki, K. Nakashiro, H. Tanaka, and et al. Knockdown of Akt isoforms by RNA silencing suppresses the growth of human prostate cancer cells in vitro and in vivo Biochem Biophys Res Commun 399 2010 79 83
20. M.W. Lee, D.S. Kim, N.Y. Min, and H.T. Kim Akt1 inhibition by RNA interference sensitizes human non-small cell lung cancer cells to cisplatin Int J Cancer 122 2008 2380 2384
21. D.D. Guo, S.H. Hong, H.L. Jiang, and et al. Synergistic effects of Akt1 shRNA and paclitaxel-incorporated conjugated linoleic acid-coupled poloxamer thermosensitive hydrogel on breast cancer Biomaterials 33 2012 2272 2281
22. Y.R. Chin, and A. Toker Function of Akt/PKB signaling to cell motility, invasion and the tumor stroma in cancer Cell Signal 21 2009 470 476
23. 3 affinity modulation Br J Cancer 107 2012 713 723
24. E.K. Kim, D.F. Tucker, S.J. Yun, and et al. Linker region of Akt1/protein kinase B alpha mediates platelet-derived growth factor-induced translocation and cell migration Cell Signal 20 2008 2030 2037
25. T.J. Abouantoun, R.C. Castellino, and T.J. MacDonald Sunitinib induces PTEN expression and inhibits PDGFR signaling and migration of medulloblastoma cells J Neurooncol 101 2011 215 226
26. N. Andrae, E. Kirches, R. Hartig, and et al. Sunitinib targets PDGF-receptor and Flt3 and reduces survival and migration of human meningioma cells Eur J Cancer 48 2012 1831 1841
27. Z. Han, L. Hong, K. Wu, and et al. Reversal of multidrug resistance of gastric cancer cells by downregulation of Akt1 with Akt1 siRNA J Exp Clin Cancer Res 25 2006 601 606
28. L. Yang, L. Xiao, X. Ma, and et al. Effect of DNAzymes targeting Akt1 on cell proliferation and apoptosis in nasopharyngeal carcinoma Cancer Biol Ther 8 2009 366 371
29. S. Boldt, U.H. Weidle, and W. Kolch The role of MAPK pathways in the action of chemotherapeutic drugs Carcinogenesis 23 2002 1831 1838
30. N. Pore, Z. Jiang, H.K. Shu, and et al. Akt1 activation can augment hypoxia-inducible factor-1alpha expression by increasing protein translation through a mammalian target of rapamycin-independent pathway Mol Cancer Res 4 2006 471 479